Bio-Rad Laboratories Quarterly Balance Sheet
NYSE: BIOHealthcareMedical DevicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bio-Rad Laboratories financial position
As of Jun 30, 2026, Bio-Rad Laboratories reported total assets of $10.25 billion, up 0.4% from a year earlier against total liabilities of $3.08 billion. Shareholders' equity stood at $7.17 billion, or 70.0% of assets. The company held $517.0 million in cash and equivalents against $803.0 million of debt, a net debt position of $286.0 million.
The current ratio (current assets divided by current liabilities) was 3.14, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.11.
Summary generated from market data by MetaCap's automated system. Methodology
Bio-Rad Laboratories balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 517.00M | 507.20M | 529.80M | 395.80M | 369.30M | 521.40M | 488.10M | 410.40M | 406.90M | 433.30M | 403.80M | 457.85M |
| Short-Term Investments | 1.10B | 1.06B | 1.01B | 1.02B | 1.00B | 1.14B | 1.18B | 1.21B | 1.21B | 1.21B | 1.20B | 1.30B |
| Receivables | 441.80M | 426.20M | 460.60M | 464.70M | 469.90M | 424.70M | 452.50M | 461.94M | 445.51M | 444.81M | 489.00M | 457.40M |
| Inventory | 780.60M | 770.50M | 740.70M | 783.20M | 798.80M | 790.10M | 760.00M | 804.28M | 803.69M | 783.37M | 780.50M | 775.82M |
| Total Current Assets | 3.02B | 2.94B | 2.91B | 2.84B | 2.81B | 3.04B | 3.03B | 3.06B | 3.06B | 3.06B | 3.05B | 3.15B |
| Property, Plant & Equipment | 517.90M | 527.50M | 539.90M | 540.20M | 549.70M | 528.50M | 528.10M | 545.30M | 533.77M | 522.36M | 529.00M | 511.39M |
| Goodwill | 574.30M | 577.10M | 579.80M | 578.70M | 581.60M | 414.60M | 410.50M | 415.10M | 412.12M | 412.82M | 413.60M | 406.95M |
| Intangible Assets | 160.00M | 166.80M | 174.30M | 388.40M | 396.90M | 296.10M | 293.60M | 307.32M | 307.09M | 313.60M | 320.50M | 314.19M |
| Long-Term Investments | 5.72B | 5.31B | 6.10B | 5.06B | 5.58B | 4.99B | 4.84B | 6.00B | 5.10B | 8.02B | 7.70B | 7.22B |
| Total Assets | 10.25B | 9.79B | 10.58B | 9.70B | 10.21B | 9.53B | 9.36B | 10.60B | 9.69B | 12.61B | 12.30B | 11.90B |
| Accounts Payable | 143.50M | 133.10M | 129.00M | 128.80M | 139.30M | 137.90M | 122.30M | 122.19M | 126.69M | 102.75M | 144.60M | 111.86M |
| Total Current Liabilities | 961.30M | 917.00M | 517.00M | 522.30M | 548.90M | 506.60M | 467.80M | 497.94M | 486.96M | 466.15M | 522.80M | 558.18M |
| Long-Term Debt | 803.00M | 802.90M | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B |
| Total Liabilities | 3.08B | 2.94B | 3.12B | 2.96B | 3.09B | 2.85B | 2.79B | 3.12B | 2.91B | 3.56B | 3.56B | 3.48B |
| Shareholders' Equity | 7.17B | 6.85B | 7.45B | 6.74B | 7.13B | 6.68B | 6.57B | 7.49B | 6.78B | 9.05B | 8.74B | 8.42B |
| Retained Earnings | 8.02B | 7.65B | 8.18B | 7.46B | 7.80B | 7.48B | 7.42B | 8.13B | 7.48B | 9.64B | 9.26B | 8.91B |
| Total Debt | 803.00M | 802.90M | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B | 1.20B |
| Net Cash (Debt) | 815.50M | 761.80M | 339.00M | 217.20M | 172.70M | 459.70M | 464.10M | 422.42M | 416.37M | 446.31M | 408.00M | 560.28M |
This table shows 12 quarterly periods of Bio-Rad Laboratories's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow BIO's reporting calendar. What is a balance sheet?